Matt Wiley
Senior Vice President and Chief Commercial Officer
Matt Wiley has over 25 years of sales, marketing, and strategy experience across multiple specialty product launches. Prior to joining BioXcel Therapeutics, he served as Chief Commercial Officer at VYNE Therapeutics, overseeing all commercial objectives related to the launch of the company’s first two approved dermatology products, AMZEEQ® and ZILXI®. Previously, he was Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals’ sleep medicine unit, where he led the go-to-market strategy and marketing team for SUNOSI™, for narcolepsy and sleep apnea, and developed the successful growth strategy for XYREM™, for narcolepsy, which achieved $1.4 billion in net revenue during his final year.
He also served as Vice President of Marketing at Azur Pharma, a specialty pharmaceutical company with a focus in central nervous system disorders, supporting the company from initiation of U.S. operations through its acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma. He holds a B.A. in English from Syracuse University.
He also served as Vice President of Marketing at Azur Pharma, a specialty pharmaceutical company with a focus in central nervous system disorders, supporting the company from initiation of U.S. operations through its acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma. He holds a B.A. in English from Syracuse University.